Brookline Capital Management Weighs in on OTLK Q1 Earnings

Outlook Therapeutics, Inc. (NASDAQ:OTLK) – Brookline Capital Management reduced their Q1 2025 earnings estimates for shares of Outlook Therapeutics in a research report issued to clients and investors on Monday, December 30th. Brookline Capital Management analyst K. Dolliver now expects that the company will post earnings of ($0.70) per share for the quarter, down from their previous forecast of ($0.62). The consensus estimate for Outlook Therapeutics’ current full-year earnings is ($3.84) per share. Brookline Capital Management also issued estimates for Outlook Therapeutics’ Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($2.00) EPS and FY2027 earnings at $1.26 EPS.

OTLK has been the subject of several other research reports. BTIG Research lowered their target price on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a research note on Friday, November 29th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Outlook Therapeutics in a research report on Friday, November 29th. Finally, Chardan Capital reissued a “neutral” rating on shares of Outlook Therapeutics in a research report on Monday, December 2nd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.73.

Outlook Therapeutics Trading Up 9.0 %

NASDAQ OTLK opened at $2.06 on Wednesday. The stock has a fifty day simple moving average of $3.53 and a 200-day simple moving average of $5.74. The stock has a market cap of $51.31 million, a PE ratio of -0.19 and a beta of 0.46. Outlook Therapeutics has a twelve month low of $0.87 and a twelve month high of $12.85.

Outlook Therapeutics (NASDAQ:OTLK) last released its quarterly earnings data on Friday, December 27th. The company reported ($0.77) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.06.

Hedge Funds Weigh In On Outlook Therapeutics

Several institutional investors have recently modified their holdings of the business. AQR Capital Management LLC acquired a new position in Outlook Therapeutics during the 2nd quarter worth $75,000. Christensen King & Associates Investment Services Inc. acquired a new stake in Outlook Therapeutics in the third quarter valued at approximately $55,000. Barclays PLC lifted its stake in Outlook Therapeutics by 677.4% in the third quarter. Barclays PLC now owns 20,943 shares of the company’s stock worth $111,000 after acquiring an additional 18,249 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Outlook Therapeutics in the 2nd quarter valued at approximately $232,000. Finally, XTX Topco Ltd acquired a new stake in shares of Outlook Therapeutics in the 3rd quarter valued at $199,000. Institutional investors and hedge funds own 11.20% of the company’s stock.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.